# A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) of TAK-228 as Single Agent in Adult East Asian Participants With Advanced Nonhematological Malignancies

> **NCT03370302** · PHASE1 · TERMINATED · sponsor: **Calithera Biosciences, Inc** · enrollment: 28 (actual)

## Conditions studied

- Advanced Nonhematological Neoplasms

## Interventions

- **DRUG:** TAK-228

## Key facts

- **NCT ID:** NCT03370302
- **Lead sponsor:** Calithera Biosciences, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-01-17
- **Primary completion:** 2019-08-28
- **Final completion:** 2019-08-28
- **Target enrollment:** 28 (ACTUAL)
- **Why stopped:** More favorable safety profile was observed in QD schedule, therefore further enrollment in QW schedule was terminated.
- **Last updated:** 2023-02-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03370302

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03370302, "A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) of TAK-228 as Single Agent in Adult East Asian Participants With Advanced Nonhematological Malignancies". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03370302. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*